Active Biotech AB (publ) (ACTI) Secures Japan Patent for Laquinimod Eye Drop to 2042
Active Biotech AB (publ) received a Japan patent (No. 7918190) covering its laquinimod ophthalmic formulation, providing potential market exclusivity in Japan until 2042. The drug targets severe inflammatory eye diseases; Phase II in uveitis is planned with a partner.Material DetailsContext by AI A…